Brian Cathers, Ph.D.

Chief Scientific Officer

Dr. Cathers joined GBT in February 2019 as chief scientific officer. He is responsible for the company’s research function, from discovery to preclinical development, and oversees all internal and external research activities. Prior to GBT, Dr. Cathers led drug discovery at Celgene’s Protein Homeostasis Thematic Center of Excellence, where his teams produced 5 new development candidates and advanced 3 investigational drugs into clinical testing in just 4 years. Before that, he oversaw enzymology and biophysical chemistry research at NewBiotics, Inc., and was part of a small team that developed a colorectal cancer drug from basic research to clinical testing in less than 3 years. He started his drug discovery career as an enzymologist at Axys Pharmaceuticals. Dr. Cathers holds a B.S. in chemistry from Emporia State University and an M.S. and a Ph.D. in medicinal chemistry from the University of Kansas. He completed his postdoctoral fellowship at the Drug Dynamics Institute at The University of Texas at Austin.